FDA grants Roches Polivy accelerated approval for people with previously treated aggressive lymphoma

FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma

Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies.

More From BioPortfolio on "FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma"